In this meta-analysis, exposure to LDL-C-lowering genetic variants in or near NPC1L1 and other genes was associated with a higher risk of type 2 diabetes. These data provide insights into potential adverse effects of LDL-C-lowering therapy.
No takes yet. Share an insight, caveat, or question.
Lotta et al. (2016) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: